ライフサイエンスコーパス: hydroxyvitamin

1 h catabolizes both 25(OH)VD(3) and 1alpha,25-hydroxyvitaminD(3).

2 stage 3-4 and vitamin D deficiency (serum 25-hydroxyvitamin D </=20 ng/ml).

3 itamin D was categorized as deficiency in 25-hydroxyvitamin D (</= 15 ng/mL), insufficiency (15-30 ng

4 h symptomatic knee osteoarthritis and low 25-hydroxyvitamin D (12.5-60 nmol/L) were enrolled from Jun

5 etermine the association between maternal 25-hydroxyvitamin D (25(OH)D) and the risk of spontaneous p

6 ty of single or predicted measurements of 25-hydroxyvitamin D (25(OH)D) concentration is unknown, as

7 vitamin D status (measured by circulating 25-hydroxyvitamin D (25(OH)D) concentration), adiposity, an

8 Here, we measured serum 25 hydroxyvitamin D (25(OH)D) concentrations in female Soay

9 ated cachexia and is detrimental to serum 25-hydroxyvitamin D (25(OH)D) concentrations in non-cancer

10 er weight loss, cachexia, and lower serum 25-hydroxyvitamin D (25(OH)D) concentrations in patients wi

11 This may be due to variations in serum 25-hydroxyvitamin D (25(OH)D) concentrations over time, inc

12 Low 25-hydroxyvitamin D (25(OH)D) has been associated with infl

13 Previous studies of serum 25-hydroxyvitamin D (25(OH)D) in relation to melanoma have

14 Low baseline plasma 25-hydroxyvitamin D (25(OH)D) is associated with increased

15 ic studies investigating the influence of 25-hydroxyvitamin D (25(OH)D) level and/or vitamin D intake

16 Research has implicated low 25-hydroxyvitamin D (25(OH)D) level as a risk factor for in

17 We investigated whether low 25-hydroxyvitamin D (25(OH)D) levels were associated with m

18 h suggested a differential association of 25-hydroxyvitamin D (25(OH)D) metabolites with type 2 diabe

19 , (2) these associations were modified by 25-hydroxyvitamin D (25(OH)D) status and explained by infla

20 izing the originally measured serum total 25-hydroxyvitamin D (25(OH)D) values from Third National He

21 e examined the association between yearly 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,2

22 rations of the major vitamin D metabolite 25 hydroxyvitamin D (25(OH)D), and a wide range of non-skel

23 ified SNPs, circulating concentrations of 25-hydroxyvitamin D (25(OH)D), and prostate cancer (3,811 c

24 dian eGFR 51 ml/min per 1.73 m(2)), serum 25-hydroxyvitamin D (25(OH)D), FGF-23, and Klotho levels we

25 e time of radical prostatectomy and serum 25-hydroxyvitamin D (25-OH D) levels.

26 Serum 25-hydroxyvitamin D (25-OHD) was measured, with VitD status

27 Low plasma 25-hydroxyvitamin D (25[OH]D) concentration is associated w

28 tation of less than 17 weeks, and a serum 25-hydroxyvitamin D (25[OH]D) concentration of 25-100 nmol/

29 exacerbation varied according to baseline 25-hydroxyvitamin D (25[OH]D) concentration, age, ethnic or

30 included all studies with measured serum 25-hydroxyvitamin D (25[OH]D) concentrations from healthy p

31 Deficient 25-hydroxyvitamin D (25[OH]D) concentrations have been asso

32 l examination, and determination of serum 25-hydroxyvitamin D (25[OH]D) concentrations.

33 Adults with low concentrations of 25-hydroxyvitamin D (25[OH]D) in blood have an increased ri

34 Secondary outcomes included the serum 25-hydroxyvitamin D (25[OH]D) level at the end of the trial

35 icovaginal HPV infection status and serum 25-hydroxyvitamin D (25[OH]D) level were known were studied

36 Low serum 25-hydroxyvitamin D (25[OH]D) levels are associated with an

37 In observational studies, higher plasma 25-hydroxyvitamin D (25[OH]D) levels have been associated w

38 second trimesters of pregnancy and serum 25-hydroxyvitamin D (25[OH]D) levels in mothers during preg

39 aseline differences between patients with 25-hydroxyvitamin D (25[OH]D) levels less than 30 ng/mL vs

40 Low 25-hydroxyvitamin D (25[OH]D) levels may represent a cause

41 25-Hydroxyvitamin D (25[OH]D) levels were measured in store

42 ograft recipients who had serum levels of 25-hydroxyvitamin D (25[OH]D) measured within the first 30

43 d 55 to 70 years, with baseline levels of 25-hydroxyvitamin D (25[OH]D) of 30 to 125 nmol/L.

44 Conversion of 25-hydroxyvitamin D (25[OH]D) to the active form of vitamin

45 Low circulating concentrations of 25-hydroxyvitamin D (25[OH]D), a marker of vitamin D status

46 We examined the distribution of serum 25-hydroxyvitamin D (25OHD) concentration and its determina

47 ass spectrometry (LC/IM-HRMS) to quantify 25-hydroxyvitamin D (25OHD) in human serum.

48 tide polymorphisms (SNPs) associated with 25-hydroxyvitamin D (25OHD) level from SUNLIGHT, the larges

49 Mean (SD) baseline blood 25-hydroxyvitamin D (25OHD) level was 63 (24) nmol/L; 25% w

50 24[A]), which conferred a large effect on 25-hydroxyvitamin D (25OHD) levels (-0.43 SD of standardize

51 morphisms (SNPs) strongly associated with 25-hydroxyvitamin D (25OHD) levels in 33,996 individuals, w

52 -nucleotide polymorphisms associated with 25-hydroxyvitamin D (25OHD) levels in the SUNLIGHT consorti

53 te a serum biomarker of vitamin D status, 25-hydroxyvitamin D (25OHD) measured at the time of breast

54 Concentrations of total 25-hydroxyvitamin D (25OHD) were assessed from maternal and

55 been linked to low levels of circulating 25-hydroxyvitamin D (25OHD), a biomarker of vitamin D statu

56 me-wide association study (GWAS) of serum 25 hydroxyvitamin D (25OHD).

57 ; in contrast, the inactive epimer, 3-epi-25-hydroxyvitamin D (epi25OHD), only adopts one.

58 nted spots was not associated with higher 25-hydroxyvitamin D (P-values > 0.05).

59 l deficiency of the Cyp27b1 gene encoding 25-hydroxyvitamin D 1-alpha-hydroxylase, which produces 1,2

60 in D receptor (rs4334089, rs11568820) and 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1: rs4646536)

61 endritic cells, engineered to overexpress 25-hydroxyvitamin D 1alpha-hydroxylase and pulsed with a my

62 ation with DCs, engineered to overexpress 25-hydroxyvitamin D 1alpha-hydroxylase for de novo synthesi

63 imum concentration of vitamin D3 or serum 25-hydroxyvitamin D [25(OH)D3] lawfully allowed in feed) on

64 s, as assessed by serum concentrations of 25-Hydroxyvitamin D [25(OH)D; comprising D(2) and D(3)] and

65 ined VDD and low vitamin D (LVD) as serum 25-hydroxyvitamin D [25(OH)D] <30 nmol/L and <50 nmol/L, re

66 ciations have been reported between serum 25-hydroxyvitamin D [25(OH)D] and circulating cholesterol c

67 nvestigate the relationship between serum 25-hydroxyvitamin D [25(OH)D] and incidence of allergic rhi

68 We assessed whether serum 25-hydroxyvitamin D [25(OH)D] at age 1 y was related to met

69 s and to study associations between serum 25-hydroxyvitamin D [25(OH)D] at different developmental st

70 ational survey that includes a measure of 25-hydroxyvitamin D [25(OH)D] by immunoassay.

71 overweight or obese, vitamin D-deficient (25-hydroxyvitamin D [25(OH)D] concentration </=50 nmol/L) a

72 Vitamin D deficiency, defined as a serum 25-hydroxyvitamin D [25(OH)D] concentration <20 ng/mL, is c

73 pulation has poor vitamin D status (serum 25-hydroxyvitamin D [25(OH)D] concentration <25 nmol/L), pa

74 ts (74%) were vitamin D deficient (plasma 25-hydroxyvitamin D [25(OH)D] concentration <50 nmol/L).

75 e, but its efficacy in maintaining infant 25-hydroxyvitamin D [25(OH)D] concentration after birth is

76 e examined the association between plasma 25-hydroxyvitamin D [25(OH)D] concentration and islet autoi

77 Serum 25-hydroxyvitamin D [25(OH)D] concentration is an indicator

78 This study aims to determine whether 25-hydroxyvitamin D [25(OH)D] concentration or the Geriatri

79 The mean +/- SD baseline plasma 25-hydroxyvitamin D [25(OH)D] concentration was 40.0 +/- 20

80 amin D intakes required to maintain serum 25-hydroxyvitamin D [25(OH)D] concentrations above proposed

81 intakes required to maintain winter serum 25-hydroxyvitamin D [25(OH)D] concentrations above the prop

82 an inverse association between low serum 25-hydroxyvitamin D [25(OH)D] concentrations and developmen

83 evious findings of an association between 25-hydroxyvitamin D [25(OH)D] concentrations and periodonta

84 The association between plasma 25-hydroxyvitamin D [25(OH)D] concentrations and prevalence

85 mined the association between circulating 25-hydroxyvitamin D [25(OH)D] concentrations and the outcom

86 ought to evaluate whether deficient serum 25 hydroxyvitamin D [25(OH)D] concentrations are associated

87 rsy exists over the disparate circulating 25-hydroxyvitamin D [25(OH)D] concentrations between black

88 his study was to examine whether maternal 25-hydroxyvitamin D [25(OH)D] concentrations in pregnancy a

89 ms, >=1 functional limitations, and serum 25-hydroxyvitamin D [25(OH)D] concentrations of 15-50/70 nm

90 vely study the association between plasma 25-hydroxyvitamin D [25(OH)D] concentrations, vitamin D-rel

91 domized controlled trials (RCTs) on serum 25-hydroxyvitamin D [25(OH)D] concentrations.

92 enes influences ultraviolet (UV)B-induced 25-hydroxyvitamin D [25(OH)D] concentrations.

93 In most studies, serum 25-hydroxyvitamin D [25(OH)D] decreases with increasing BMI

94 en described as being pandemic, but serum 25-hydroxyvitamin D [25(OH)D] distribution data for the Eur

95 er, so far, it is not clear whether serum 25-hydroxyvitamin D [25(OH)D] exerts any beneficial effect

96 The level of serum 25-Hydroxyvitamin D [25(OH)D] has high heritability, sugges

97 al evidence supports a protective role of 25-hydroxyvitamin D [25(OH)D] in breast carcinogenesis, but

98 The role of maternal 25-hydroxyvitamin D [25(OH)D] in fetal development is uncer

99 clinical significance of low circulating 25-hydroxyvitamin D [25(OH)D] in obese people are unknown.

100 g protein (DBP) is the primary carrier of 25-hydroxyvitamin D [25(OH)D] in the circulation.

101 D], the active vitamin D metabolite, from 25-hydroxyvitamin D [25(OH)D] in the kidney.

102 Epidemiologic data suggest that low serum 25-hydroxyvitamin D [25(OH)D] increases insulin resistance

103 Low 25-hydroxyvitamin D [25(OH)D] is associated with diabetes,

104 It remains unclear whether 25-hydroxyvitamin D [25(OH)D] level is associated with CMV

105 Mean (SD) baseline blood 25-hydroxyvitamin D [25(OH)D] level was 63 (24) nmol/L; 25%

106 min D deficiency (baseline deseasonalized 25-hydroxyvitamin D [25(OH)D] levels <20 ng/mL).

107 ed the association between baseline serum 25-hydroxyvitamin D [25(OH)D] levels, supplemental vitamin

108 ncertain because of nonstandardized serum 25-hydroxyvitamin D [25(OH)D] measurements.

109 ciation between prediagnostic circulating 25-hydroxyvitamin D [25(OH)D] serum levels and the risk of

110 ed and reference values for the following 25-hydroxyvitamin D [25(OH)D] species: 25(OH)D2, 25(OH)D3,

111 Concentrations of 25-hydroxyvitamin D [25(OH)D] tend to be lower in African A

112 Serum 25-hydroxyvitamin D [25(OH)D] was measured and a level of u

113 Serum 25-hydroxyvitamin D [25(OH)D] was measured at enrollment, a

114 Maternal 25-hydroxyvitamin D [25(OH)D] was positively associated wit

115 oratory models, the association of plasma 25-hydroxyvitamin D [25(OH)D] with patient survival is larg

116 d the risk of dementia.We measured plasma 25-hydroxyvitamin D [25(OH)D] with the use of high-performa

117 amin D) and 25-hydroxivitamin D2 plus D3 (25-hydroxyvitamin D [25(OH)D]) in foremilk and hindmilk dur

118 e evaluated the association between serum 25-hydroxyvitamin D [25(OH)D], a marker of vitamin D status

119 measured concentrations of ascorbic acid, 25-hydroxyvitamin D [25(OH)D], and erythrocyte membrane fat

120 takes, fasting serum parathyroid hormone, 25-hydroxyvitamin D [25(OH)D], and ionized calcium were com

121 to assess the associations between serum 25-hydroxyvitamin D [25(OH)D], BMI, and 16 inflammatory bio

122 g and maintaining serum concentrations of 25-hydroxyvitamin D [25(OH)D], particularly at lower doses

123 from baseline in serum ferritin (SF) and 25-hydroxyvitamin D [25(OH)D], respectively.

124 opometric measures, blood pressure, serum 25-hydroxyvitamin D [25(OH)D], total cholesterol, HDL chole

125 n in older adults with low baseline serum 25-hydroxyvitamin D [25(OH)D].

126 ge and both BMI z score (zBMI) and venous 25-hydroxyvitamin D [25(OH)D]; the secondary objective was

127 The effects of serum vitamin D (25-hydroxyvitamin D [25OHD]) levels on preeclampsia inciden

128 ldren >4 y of age attain sufficient serum 25-hydroxyvitamin D [S-25(OH)D; i.e., >/=50 nmol/L] during

129 us in Finland between 2000 and 2011.Serum 25-hydroxyvitamin D [S-25(OH)D] concentrations of a nationa

130 Mean (+/- SD) serum total 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels were

131 The 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels were

132 Mean calculated bioavailable 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D were 2.5 +/

133 pplementation rapidly and safely improves 25-hydroxyvitamin D and bioavailable 25-hydroxyvitamin D le

134 evidence of association between change in 25-hydroxyvitamin D and change in 24-hour systolic blood pr

135 at sample collection, and maternal serum 25-hydroxyvitamin D and cotinine levels.

136 id not indicate that associations between 25-hydroxyvitamin D and features of skin aging are causal.

137 This study investigated whether lower 25-hydroxyvitamin D and higher parathyroid hormone concentr

138 elation was observed between bioavailable 25-hydroxyvitamin D and LL-37 (Spearman rho = 0.44; p = 0.0

139 n rho = 0.44; p = 0.03) but not for total 25-hydroxyvitamin D and LL-37.

140 y and at 4 and 12 mo postpartum for serum 25-hydroxyvitamin D and markers of bone turnover.

141 By contrast, 25-hydroxyvitamin D and other markers of mineral metabolism

142 teraction between serum concentrations of 25-hydroxyvitamin D and s-retinol on hip fracture was obser

143 iabetes, parity, or circulating levels of 25-hydroxyvitamin D and sex hormone binding globulin with o

144 Associations between 25-hydroxyvitamin D and skin aging features were tested by

145 Changes in bioavailable 25-hydroxyvitamin D are associated with concomitant increas

146 y age with changes in adiposity and serum 25-hydroxyvitamin D as primary or secondary outcomes were c

147 Variability across studies in 25-hydroxyvitamin D assays and baseline levels, treatment d

148 At a broad population level, 25-hydroxyvitamin D at birth was not associated with risk o

149 -tryptophan, kynurenic acid, taurine, and 25-hydroxyvitamin D compared with controls.

150 st-hip ratio, vitamin D deficiency (serum 25-hydroxyvitamin D concentration <10 ng/mL), lack of outdo

151 Serum 25-hydroxyvitamin D concentration (per 10-nmol/L increment:

152 In contrast, a genetically determined 25-hydroxyvitamin D concentration was not associated with a

153 BP variability and serum 25-hydroxyvitamin D concentration were examined in a post h

154 In addition, vitamin D inadequacy (serum 25-hydroxyvitamin D concentration, averaged across pregnanc

155 ressure (BP) among individuals with lower 25-hydroxyvitamin D concentration.

156 Few subjects had 25-hydroxyvitamin D concentrations <30 nmol/L.

157 The intervention elevated 8-week serum 25-hydroxyvitamin D concentrations (154.5 nmol/L vs. 15.2 n

158 m tartrate-resistant acid phosphatase and 25-hydroxyvitamin D concentrations (P < 0.01).

159 her there are causal associations between 25-hydroxyvitamin D concentrations and features of skin agi

160 with HIV who initiated ART and had serum 25-hydroxyvitamin D concentrations of less than 30 ng/mL at

161 ation in participants with baseline serum 25-hydroxyvitamin D concentrations of less than 50 nmol/L (

162 Lower 25-hydroxyvitamin D concentrations were not associated with

163 Plasma total 25-hydroxyvitamin D concentrations were originally determin

164 Dose-response increases in serum 25-hydroxyvitamin D concentrations were significant and tol

165 ontrolling for baseline bone value, serum 25-hydroxyvitamin D concentrations, length of breastfeeding

166 Further studies evaluating 25-hydroxyvitamin D concentrations, other dairy constituent

167 observed at 28.7 ng/mL of achieved serum 25-hydroxyvitamin D concentrations.

168 ive factor, serum calcium, or circulating 25-hydroxyvitamin D concentrations.

169 We used serum 25-hydroxyvitamin D data from NHANES 2011-2014 (n = 16,180)

170 In the full cohort, 25-hydroxyvitamin D deficiency is a significant predictor f

171 Preadmission 25-hydroxyvitamin D deficiency is predictive for the risk o

172 25-hydroxyvitamin D deficiency prior to hospital admission

173 al of each platform for the separation of 25-hydroxyvitamin D epimers.

174 from long chromatography time to separate 25-hydroxyvitamin D from its inactive epimer; however, ion

175 Low levels of 25-hydroxyvitamin D have been associated with higher risk f

176 Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease (CLEAR), NCT0

177 The level of 25-hydroxyvitamin D increased more in the vitamin D group (

178 Serum 25-hydroxyvitamin D increased to a similar extent in both g

179 uantitation of the serum concentration of 25-hydroxyvitamin D is a high-demand assay that suffers fro

180 Serum levels of 25-hydroxyvitamin D l <20 ng/ml are diagnostic of vitamin D

181 upport an association between a low blood 25-hydroxyvitamin D level and the risk of type 2 diabetes.

182 The median 25-hydroxyvitamin D level at baseline was 15.3 ng/mL.

183 stratification according to the maternal 25-hydroxyvitamin D level during pregnancy.

184 By month 24, the mean serum 25-hydroxyvitamin D level in the vitamin D group was 54.3 n

185 al older women with a mean baseline serum 25-hydroxyvitamin D level of 32.8 ng/mL, supplementation wi

186 Vitamin D supplementation, but not serum 25-hydroxyvitamin D level or milk intake, was associated wi

187 All patients included had a total 25-hydroxyvitamin D level recorded.

188 , 1078 had baseline vitamin D deficiency (25-hydroxyvitamin D level, <20 ng per milliliter [50 nmol p

189 65.2 years [SD, 7.0]; mean baseline serum 25-hydroxyvitamin D level, 32.8 ng/mL [SD, 10.5]), 2064 (90

190 placebo, regardless of the baseline serum 25-hydroxyvitamin D level.

191 0 years of age with low vitamin D status (25-hydroxyvitamin D levels </=25 ng/mL) and systolic blood

192 ogical studies support a link between low 25-hydroxyvitamin D levels and a higher risk of viral upper

193 er respiratory tract infection, and serum 25-hydroxyvitamin D levels at study termination.

194 Low 25-hydroxyvitamin D levels correlate with the prevalence of

195 oves 25-hydroxyvitamin D and bioavailable 25-hydroxyvitamin D levels in patients with severe sepsis o

196 se inhaled corticosteroids and with serum 25-hydroxyvitamin D levels less than 30 ng/mL.

197 lood levels were checked, 289 (74.9%) had 25-hydroxyvitamin D levels of 30 ng/mL or higher by the thi

198 Despite achieving 25-hydroxyvitamin D levels of 41.9 ng/ml (95% confidence in

199 itamin D had a mean net increase in serum 25-hydroxyvitamin D levels of 7.83 ng per milliliter, relat

200 p=0.021), but not in those with baseline 25-hydroxyvitamin D levels of at least 50 nmol/L (1.45, 0.8

201 tion, in patients with COPD with baseline 25-hydroxyvitamin D levels of less than 50 nmol/L.

202 At year 1, serum 25-hydroxyvitamin D levels were 43.9 ng/mL in the vitamin D

203 At study termination, serum 25-hydroxyvitamin D levels were 48.7 ng/mL (95% CI, 46.9-50

204 BMD by dual-energy x-ray absorptiometry, 25-hydroxyvitamin D levels, and other laboratory assessment

205 tomatic knee osteoarthritis and low serum 25-hydroxyvitamin D levels, vitamin D supplementation, comp

206 s of age and (2) third trimester maternal 25-hydroxyvitamin D levels.

207 sociation between obesity and lower serum 25-hydroxyvitamin D may be due to reversed causation with i

208 ndings: Initial evaluation should include 25-hydroxyvitamin D measurement, 24-hour urine calcium meas

209 (24R),25(OH)2D3) is a major catabolite of 25-hydroxyvitamin D metabolism and is an important vitamin

210 ld, contrasting the stimulatory effect of 25-hydroxyvitamin D or 1,25-dihydroxyvitamin D on related a

211 hepatocytes or monocytes with prohormone 25-hydroxyvitamin D or active 1,25-dihydroxyvitamin D decre

212 n was found between BMD and current serum 25-hydroxyvitamin D or dietary intake of calcium, protein,

213 In chromatin immunoprecipitation assays, 25-hydroxyvitamin D promoted binding of the vitamin D recep

214 017, 6250 adults initiating ART had serum 25-hydroxyvitamin D screening, 4000 of whom were enrolled i

215 We investigated whether 25-hydroxyvitamin D serum concentration was a modifiable ri

216 zed in the liver through hydroxylation to 25-hydroxyvitamin D species, and then further hydroxylated

217 ion between allocation and baseline serum 25-hydroxyvitamin D status).

218 94]; p = 0.001) relative to patients with 25-hydroxyvitamin D sufficiency.

219 tamin D, local osteoblastic conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D appears to b

220 line, median (interquartile range) plasma 25-hydroxyvitamin D was 17 ng/mL (13-22 ng/mL) and peaked b

221 The mean day 3 level of 25-hydroxyvitamin D was 46.9+/-23.2 ng per milliliter (117+

222 wo cohorts, we observed that higher serum 25-hydroxyvitamin D was associated with a higher perceived

223 : Preadmission 25-hydroxyvitamin D was categorized as deficiency in 25-hyd

224 tography-tandem mass spectrometry method, 25-hydroxyvitamin D was measured in stored baseline serum s

225 ect of weight loss on the change in serum 25-hydroxyvitamin D was shown overall.

226 olecalciferol-treated patients, change in 25-hydroxyvitamin D was strongly correlated with change in

227 calcium (Ca), inorganic phosphate (Pi) or 25-hydroxyvitamin D were observed, whereas bone alkaline ph

228 Serum concentrations of vitamin A and 25-hydroxyvitamin D were significantly reduced after duoden

229 etermine whether, when maternal levels of 25-hydroxyvitamin D were taken into account, children born

230 e resulted in a greater increase in serum 25-hydroxyvitamin D with a mean difference of 3.11 nmol/L (

231 tes, demonstrated an association of total 25-hydroxyvitamin D with hospital length of stay (incident

232 emained significant associations of total 25-hydroxyvitamin D with readmission (odds ratio per 1 ng/m

233 25-Hydroxyvitamin D(2) (25(OH)D(2)) and 25-Hydroxyvitamin D

234 25-Hydroxyvitamin D(2) (25(OH)D(2)) and 25-Hydroxyvitamin D(3) (25(OH)D(3)) concentrations were det

235 er the irradiation and assessed for serum 25-hydroxyvitamin D(3) (25[OH]D(3)) as a marker of vitamin

236 he link between season of birth, neonatal 25-hydroxyvitamin D(3) [25(OH)D(3)] status, and adult cardi

237 Megalin mediates 25-hydroxyvitamin D(3) actions in human mesenchymal stem ce

238 N-terminal pro-brain natriuretic peptide, 25-hydroxyvitamin D) and 2 nonhormones (prostate-specific a

239 and high circulating levels of calcidiol (25-hydroxyvitamin D) each increased serum FGF23 levels in w

240 ajor circulating metabolite of vitamin D (25-hydroxyvitamin D) is converted to the active form (calci

241 arkers (parathyroid hormone, calcium, and 25-hydroxyvitamin D), and annualized BMD reduction over a 8

242 , respectively, were as follows: 1) total 25-hydroxyvitamin D, 3% (-3% to 8%), 49% (30-82%), and 69%

243 9% (55-106%) (p < 0.001); 2) bioavailable 25-hydroxyvitamin D, 4% (-8% to 7%), 45% (40-70%), and 96%

244 TH), fibroblast growth factor 23 (FGF23), 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D (1,25D) pr

245 and on days 3, 5, and 7, to assess total 25-hydroxyvitamin D, as well as vitamin D-binding protein a

246 he addition of serum calcium, phosphorus, 25-hydroxyvitamin D, intact parathyroid hormone, and 24,25-

247 ect of high circulating concentrations of 25-hydroxyvitamin D, local osteoblastic conversion of 25-hy

248 iomarkers on the metabolic pathway (e.g., 25-hydroxyvitamin D, parathyroid hormone, phosphorus) had l

249 nd albumin), and bone mineral metabolism (25-hydroxyvitamin D, phosphorus, calcium, and parathyroid h

250 ce of TNF-alpha generated calcitriol from 25-hydroxyvitamin D, resulting in repression of MerTK expre

251 birth, breastfeeding) and in adult life (25-hydroxyvitamin D, sun exposure, vitamin D intake from da

252 idney stones was not modified by baseline 25-hydroxyvitamin D, vitamin D dose and duration, or calciu

253 abundant arachidonate 15-lipoxygenase and 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial.

254 ivity, plasma C-peptide, adiponectin, and 25-hydroxyvitamin D.

255 maintenance leads to an increase in serum 25-hydroxyvitamin D.

256 ein and albumin to calculate bioavailable 25-hydroxyvitamin D.

257 re or any interaction between retinol and 25-hydroxyvitamin D.

258 e excretion and inhibits hydroxylation of 25-hydroxyvitamin D.

259 tion and regulates the bioavailability of 25-hydroxyvitamin D.

260 ations were not confounded or modified by 25-hydroxyvitamin D.

261 n D 1-alpha-hydroxylase, which produces 1,25-hydroxyvitamin D.

262 ciated with lower concentrations of serum 25-hydroxyvitamin D; however, uncertainty exists as to the

263 25-Hydroxyvitamin-D (25(OH)D) level was measured in early a

264 /MS) method for measuring 25(OH)D (sum of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3), calibrated

265 t-soluble vitamins all-trans retinol (A), 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, alpha-tocophero

266 (LOD) for the low-concentration analytes (25-hydroxyvitamin D2, 25-hydroxyvitamin D3, and phylloquino

267 eficiency was defined as a serum level of 25-hydroxyvitamin D3 < 20 ng/mL (equivalent to < 50 nM) bef

268 Intervention with a single dose of 25-hydroxyvitamin D3 (25(OH)D) is capable of suppressing ma

269 , we used a case-cohort design to compare 25-hydroxyvitamin D3 (25(OH)D3 ) levels among infants with

270 We assessed whether 25-hydroxyvitamin D3 (25(OH)D3) was associated with risk of

271 with low levels of glutathione (GSH) and 25-hydroxyvitamin D3 (25(OH)VD(3)).

272 fferent races and the association between 25-hydroxyvitamin D3 (25[OH]D) levels in pregnancy and the

273 nvestigated the association between serum 25-hydroxyvitamin D3 (25[OH]D3) levels and food allergy at

274 Three hundred fifty-nine pretreatment 25-hydroxyvitamin D3 (25[OH]D3) serum levels from the RICOV

275 precursor metabolite in the circulation, 25-hydroxyvitamin D3 (25OHD3), can influence IgE-mediated m

276 synthesize calcitriol from its precursor 25-hydroxyvitamin D3 (inactive precursor) [25(OH)D] upon an

277 Higher concentrations of 25-hydroxyvitamin D3 [25(OH)D3] at diagnosis are associated

278 tion during childhood.We examined whether 25-hydroxyvitamin D3 [25(OH)D3] concentrations in stored ne

279 25-Hydroxyvitamin D3 [25(OH)D3] has recently been found to

280 tion of target genes.In placental tissue, 25-hydroxyvitamin D3 [25(OH)D3] was strongly correlated (r

281 We described the distribution of 25-hydroxyvitamin D3 [25(OH)D3], 3-epi-25(OH)D3, and 25(OH)

282 skin of female mice and normalized serum 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 levels, a

283 25-Hydroxyvitamin D3 and D2 were quantified over the range

284 rds having more access to sunlight, while 25-hydroxyvitamin D3 concentration was higher (P<0.05) only

285 25-hydroxyvitamin D3 concentrations were significantly lowe

286 in D3 metabolism at all stages and plasma 25-hydroxyvitamin D3 depletion in the acute and latent phas

287 1alpha-Hydroxyvitamin D3 did not increase OCR.

288 isease (CLEAR), NCT02937350; Clearance of 25-hydroxyvitamin D3 During Vitamin D3 Supplementation (CLE

289 estigated the retention of vitamin D3 and 25-hydroxyvitamin D3 in eggs, vitamin D3 in margarine, and

290 Levels of 25-hydroxyvitamin D3 increased with vitamin D3 plus calcium

291 A significant difference in 25-Hydroxyvitamin D3 levels was detected between GS patient

292 had significantly lower concentrations of 25-hydroxyvitamin D3 than patients with either mild sepsis

293 Concentration of 25-hydroxyvitamin D3 was higher (P<0.05) in July and Septem

294 25(OH)D (sum of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3), calibrated to standard reference mat

295 -trans retinol (A), 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, alpha-tocopherol (E), gamma-tocophero

296 king a 1alpha-hydroxyl group (vitamin D3, 25-hydroxyvitamin D3, and 24R,25-dihydroxyvitamin D3) decre

297 entration analytes (25-hydroxyvitamin D2, 25-hydroxyvitamin D3, and phylloquinone) were 25, 17, and 0

298 ), is synthesized by the essential enzyme 25-hydroxyvitamin D3-1alpha-hydroxylase (CYP27B1), which ca

299 ions in the vitamin D catabolizing enzyme 25-hydroxyvitamin D3-24-hydroxylase (CYP24A1) were describe

300 te on the concentration of vitamin D3 and 25-hydroxyvitamin D3.